NONMEM Users Network Archive

Hosted by Cognigen

Re: Bayesian estimation example

From: Krishna Devarakonda <dr_krishna>
Date: Fri, 13 Apr 2007 04:41:52 +0530

Analysis of the data (perform PK analysis on individual subject data &
obtaib mean parameters) from initial studies in voulnteers helps in NONMEM
analysis of the data from 200 patients. If the data points are widely
distributed (entire time range) it is possible to get reasonable estimates
of average (pop) values of PK parameters and to study the influence of
different covariates. It is advisable to run both FO & FOCE estimations.
Plz. read this article: http://www.aapsj.org/view.asp?art=aapsj0901007 in
which a survey on different analysis methods (including Bayesian) has been
well described by Bauer et al.,
- Best wishes,
Krishna R Devarakonda, PhD
Division of Pharmacology & Clinical Pharmacy,
Kakatiya University,
University College of Pharm. Sci.,
WARANGAL 506 009



----- Original Message -----
From: Tausif Ahmed <tausif.ahmed
To: <nmusers
Sent: Thursday, April 12, 2007 4:33 PM
Subject: RE: [NMusers] Bayesian estimation example



Dear Group members,

I will make my objective more clear- I have a drug X in which I have
information in healthy volunteers with extensive sampling done, single
dose (12-14 samples).
I have data on appx. 100 volunteers at different dose levels from phase
I studies.
We also have a data in 16 patients at one dose only, with extensive
sampling.
Now we have data from 200 patients, with 2-3 blood samples collected
from each patient at different doses.
It is also seen that the PK changes in patients.
What I am interested is that can we use Bayesian estimates, (and I think
posthoc estimate from NONMEM, as Yaning mentions) to determine the
pharmacokinetics (PK) of the whole population from these 2-3 blood
samples collected per patient.
Hope it is more clear.
I have checked at website- (http://www.accp1.org/)as suggested by many
but could not find any control stream on Bayesian. Can the group help me
on this.
I thank the experts for giving their comments on the same.

Regards
Tausif Ahmed Ph.D.
Metabolism and Pharmacokinetics Department
Ranbaxy Research Lab India

-----Original Message-----
From: Wang, Yaning [mailto:yaning.wang
Sent: Wednesday, April 11, 2007 8:30 PM
To: Nick Holford; Tausif Ahmed
Subject: RE: [NMusers] Bayesian estimation example

Nick:
Tausif may be referring to the posthoc estimate from NONMEM (empirical
Bayesian estimate).
Yaning


-----Original Message-----
From: owner-nmusers
On Behalf Of Nick Holford
Sent: Wednesday, April 11, 2007 10:43 AM
To: Tausif Ahmed
Cc: nmusers
Subject: Re: [NMusers] Bayesian estimation example

Tausif,

Why do you want to use Bayesian Estimation? If you have only just
started to use NONMEM then perhaps you have misunderstood the reasons
for using it. It is very rarely needed.

Nick

> Dear Group members,
>
> I have recently started using NONMEM for population analysis.
> I need you help in understanding Bayesian estimation using NONMEM.
> Can any body provide me a sample control stream along with data file
(Excel or csv format) and also explain the output.
> I use Visual NM to run NONMEM version V.
>
> Thanking you in anticipation.
>
> Regards
> Tausif Ahmed Ph.D.
> Metabolism and Pharmacokinetics Department Ranbaxy Research Lab India

--
Nick Holford, Dept Pharmacology & Clinical Pharmacology University of
Auckland, 85 Park Rd, Private Bag 92019, Auckland, New Zealand
email:n.holford
http://www.health.auckland.ac.nz/pharmacology/staff/nholford/



(i) The information contained in this e-mail message is intended only for
the confidential use of the recipient(s) named above. This message is
privileged and confidential. If the reader of this message is not the
intended recipient or an agent responsible for delivering it to the intended
recipient, you are hereby notified that you have received this document in
error and that any review, dissemination, distribution, or copying of this
message is strictly prohibited. If you have received this communication in
error, please notify us immediately by e-mail, and delete the original
message.


 (ii) The sender confirms that Ranbaxy shall not be responsible if this
email message is used for any indecent, unsolicited or illegal purposes,
which are in violation of any existing laws and the same shall solely be the
responsibility of the sender and that Ranbaxy shall at all times be
indemnified of any civil and/ or criminal liabilities or consequences there.
Received on Thu Apr 12 2007 - 19:11:52 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request@iconplc.com.

Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.